Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! By
First Iranian Guidelines for the Diagnosis, Management, and Treatment of Hyperlipidemia in Adults Publisher



Bagheri Kholenjani F1 ; Shahidi S1 ; Vaseghi G2 ; Ashoorion V3 ; Sarrafzadegan N1, 2, 3, 4 ; Siavash M5 ; Heidarpour M5 ; Shahidi S1 ; Sadeghi M7 ; Mohammadifard N8 ; Jorjani M9 ; Mobarhan MG10 ; Shafie D11 ; Farshidi H12 Show All Authors
Authors
  1. Bagheri Kholenjani F1
  2. Shahidi S1
  3. Vaseghi G2
  4. Ashoorion V3
  5. Sarrafzadegan N1, 2, 3, 4
  6. Siavash M5
  7. Heidarpour M5
  8. Shahidi S1
  9. Sadeghi M7
  10. Mohammadifard N8
  11. Jorjani M9
  12. Mobarhan MG10
  13. Shafie D11
  14. Farshidi H12
  15. Khorvash F13
  16. Ghabaei M14
  17. Teimourijervekani Z1
  18. Mortazavi M15
  19. Hajhashemi V16
  20. Roshanravan N17
  21. Yazdanpanah L18
  22. Davari M19
  23. Fatemi B19
  24. Khorasani E20
  25. Hoseinkhani R21
  26. Zarean E22
  27. Ahmadi A23
  28. Babadi ME24
  29. Assareh A25
  30. Shadmani M26
  31. Kojuri J27
  32. Shirani F24
  33. Sanjari M28
  34. Haghighatdoost F29
  35. Hassannejad R1
  36. Hashemi E30
  37. Moaddab MH31
  38. Gheisari A32
  39. Dehghan B23
  40. Naseri M33
  41. Ghaemi N34
  42. Noohi F4, 35
  43. Haghdoost A36
  44. Salehiabargouei A37
  45. Beigrezaie S38
  46. Doostiirani A39
  47. Ramezanijolfaie N40
  48. Eraj B41
  49. Hashemipour M30
  50. Nematipour E42
  51. Kopaei MR43

Source: Journal of Research in Medical Sciences Published:2024


Abstract

This guideline is the first Iranian guideline developed for the diagnosis, management, and treatment of hyperlipidemia in adults. The members of the guideline developing group (GDG) selected 9 relevant clinical questions and provided recommendations or suggestions to answer them based on the latest scientific evidence. Recommendations include the low‑density lipoprotein cholesterol (LDL‑C) threshold for starting drug treatment in adults lacking comorbidities was determined to be over 190 mg/dL and the triglyceride (TG) threshold had to be >500 mg/dl. In addition to perform fasting lipid profile tests at the beginning and continuation of treatment, while it was suggested to perform cardiovascular diseases (CVDs) risk assessment using valid Iranian models. Some recommendations were also provided on lifestyle modification as the first therapeutic intervention. Statins were recommended as the first line of drug treatment to reduce LDL‑C, and if its level was high despite the maximum allowed or maximum tolerated drug treatment, combined treatment with ezetimibe, proprotein convertase subtilisin/kexin type 9 inhibitors, or bile acid sequestrants was suggested. In adults with hypertriglyceridemia, pharmacotherapy with statin or fibrate was recommended. The target of drug therapy in adults with increased LDL‑C without comorbidities and risk factors was considered an LDL‑C level of <130 mg/dl, and in adults with increased TG without comorbidities and risk factors, TG levels of <200 mg/dl. In this guideline, specific recommendations and suggestions were provided for the subgroups of the general population, such as those with CVD, stroke, diabetes, chronic kidney disease, elderly, and women. © 2024 Journal of Research in Medical Sciences.
Other Related Docs
19. Non-Alcoholic Fatty Liver Disease (Nafld) and 10-Year Risk of Cardiovascular Diseases, Clinics and Research in Hepatology and Gastroenterology (2017)